Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Recurrent manic-depressive illness requires effective long-term prophylactic treatment.
• Lithium is a standard prophylactic treatment but has limitations including side effects and compliance issues.
• Flupenthixol decanoate is an antipsychotic with potential prophylactic applications.

Purpose of the Study:

• To evaluate flupenthixol decanoate as a prophylactic alternative to lithium in bipolar disorder.
• To compare the efficacy of lithium versus flupenthixol decanoate in a randomized group.
• To assess flupenthixol decanoate in patients with prior inadequate lithium treatment.

Main Methods:

• Two patient groups were studied: Group I (randomized lithium vs. flupenthixol decanoate) and Group II (switched from lithium to flupenthixol decanoate).
• Flupenthixol decanoate was administered at 20 mg every 2-3 weeks.
• The study was not blinded.

Main Results:

• In Group I, neither lithium nor flupenthixol decanoate significantly reduced episode frequency or time ill.
• In Group II, flupenthixol decanoate significantly decreased manic episodes and time ill in mania.
• Group II also showed a significant increase in depressive episodes and time ill in depression, particularly in those previously on lithium.

Conclusions:

• Flupenthixol decanoate's prophylactic value in bipolar disorder remains uncertain.
• It may be considered for patients with predominantly manic recurrences who are non-responsive or intolerant to lithium.
• Further research is needed to clarify its role and manage potential increases in depressive morbidity.